sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
bromelains
|
phenytoin
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p388
|
There is thus an enhancement effect of PGF2alpha upon the reaction of placental vessels to oxytocin in vitro.
|
PGF2alpha
|
oxytocin
|
EFFECT
|
1113260.xml
|
DDI-MedLine.d17.s9
|
DDI-MedLine.d17.s9.p0
|
Bismuth: Bismuth subsalicylate, given concomitantly with enoxacin or 60 minutes following enoxacin administration, decreased enoxacin bioavailability by approximately 25%.
|
Bismuth subsalicylate
|
enoxacin
|
MECHANISM
|
Enoxacin_ddi.xml
|
DDI-DrugBank.d395.s0
|
DDI-DrugBank.d395.s0.p4
|
Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg (three 333-mg capsules) every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.
|
rifabutin
|
CRIXIVAN
|
NONE
|
Indinavir_ddi.xml
|
DDI-DrugBank.d97.s84
|
DDI-DrugBank.d97.s84.p0
|
Caution should be exercised if tacrolimus and bosentan are used together.
|
tacrolimus
|
bosentan
|
ADVISE
|
Bosentan_ddi.xml
|
DDI-DrugBank.d289.s16
|
DDI-DrugBank.d289.s16.p0
|
Therefore, co-administration of clozapine with other drugs that are metabolized by this isozyme, including antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
|
propafenone
|
quinidine
|
NONE
|
Clozapine_ddi.xml
|
DDI-DrugBank.d480.s30
|
DDI-DrugBank.d480.s30.p32
|
Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.
|
Phenobarbital
|
AEDs
|
NONE
|
Tiagabine_ddi.xml
|
DDI-DrugBank.d277.s12
|
DDI-DrugBank.d277.s12.p4
|
Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
|
SPRYCEL
|
erythromycin
|
MECHANISM
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s1
|
DDI-DrugBank.d48.s1.p2
|
Anabolic steroids (particularly C-17 alkylated androgens such as oxymetholone, methandrostenolone, norethandrolone, and similar compounds) enhanced tendency toward edema.
|
androgens
|
methandrostenolone
|
NONE
|
Fludrocortisone_ddi.xml
|
DDI-DrugBank.d526.s19
|
DDI-DrugBank.d526.s19.p5
|
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
|
serotonin reuptake inhibitors
|
SSRIs
|
NONE
|
Amitriptyline_ddi.xml
|
DDI-DrugBank.d99.s8
|
DDI-DrugBank.d99.s8.p0
|
Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
|
Nardil
|
Eldepryl
|
NONE
|
L-Tryptophan_ddi.xml
|
DDI-DrugBank.d63.s0
|
DDI-DrugBank.d63.s0.p41
|
Drugs which may enhance the neuromuscular blocking action of TRACRIUM include: enflurane;isoflurane;halothane;certain antibiotics, especially the aminoglycosides and polymyxins;lithium;magnesium salts;procainamide;and quinidine.
|
TRACRIUM
|
enflurane
|
EFFECT
|
Atracurium_ddi.xml
|
DDI-DrugBank.d469.s7
|
DDI-DrugBank.d469.s7.p0
|
The daily dose of ENABLEX should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin and nefazadone) .
|
ENABLEX
|
clarithromycin
|
ADVISE
|
Darifenacin_ddi.xml
|
DDI-DrugBank.d459.s0
|
DDI-DrugBank.d459.s0.p4
|
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.
|
nonsteroidal anti-inflammatory drugs
|
ardeparin
|
EFFECT
|
Ardeparin_ddi.xml
|
DDI-DrugBank.d105.s0
|
DDI-DrugBank.d105.s0.p11
|
Urinary acidifying agents These agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.
|
sodium acid phosphate
|
amphetamine
|
MECHANISM
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s0
|
DDI-DrugBank.d158.s0.p2
|
The uptake inhibitors cocaine and desipramine (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium.
|
desipramine
|
norepinephrine
|
EFFECT
|
7798493.xml
|
DDI-MedLine.d94.s12
|
DDI-MedLine.d94.s12.p2
|
The concomitant use of ENABLEX with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision and other anticholinergic pharmacological effects.
|
ENABLEX
|
anticholinergic agents
|
EFFECT
|
Darifenacin_ddi.xml
|
DDI-DrugBank.d459.s2
|
DDI-DrugBank.d459.s2.p0
|
The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.
|
fentanyl
|
itraconazole
|
MECHANISM
|
Fentanyl_ddi.xml
|
DDI-DrugBank.d170.s2
|
DDI-DrugBank.d170.s2.p2
|
When the STADOL NS was administered 30 minutes after the sumatriptan nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.
|
STADOL NS
|
sumatriptan
|
MECHANISM
|
Butorphanol_ddi.xml
|
DDI-DrugBank.d246.s5
|
DDI-DrugBank.d246.s5.p0
|
Atorvastatin: Atorvastatin increases the AUC for norethindrone and ethinyl estradiol.
|
Atorvastatin
|
ethinyl estradiol
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s16
|
DDI-DrugBank.d485.s16.p4
|
Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.
|
Anesthetics
|
sedatives
|
NONE
|
Dexmedetomidine_ddi.xml
|
DDI-DrugBank.d197.s1
|
DDI-DrugBank.d197.s1.p5
|
Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).
|
Acarbose
|
digoxin
|
NONE
|
Acarbose_ddi.xml
|
DDI-DrugBank.d536.s8
|
DDI-DrugBank.d536.s8.p1
|
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.
|
PROLEUKIN
|
antineoplastic agents
|
EFFECT
|
Aldesleukin_ddi.xml
|
DDI-DrugBank.d114.s5
|
DDI-DrugBank.d114.s5.p0
|
Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.
|
oxyphenbutazone
|
androgens
|
MECHANISM
|
Fluoxymesterone_ddi.xml
|
DDI-DrugBank.d355.s2
|
DDI-DrugBank.d355.s2.p0
|
Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
|
indinavir
|
cisapride
|
MECHANISM
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s12
|
DDI-DrugBank.d237.s12.p5
|
The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium.
|
diuretic
|
fosinopril sodium
|
EFFECT
|
Fosinopril_ddi.xml
|
DDI-DrugBank.d176.s1
|
DDI-DrugBank.d176.s1.p0
|
Azlocillin should not be administered concomitantly with amikacin, ciprofloxacin, gentamicin, netilmicin, or tobramycin.
|
Azlocillin
|
tobramycin
|
ADVISE
|
Azlocillin_ddi.xml
|
DDI-DrugBank.d9.s0
|
DDI-DrugBank.d9.s0.p4
|
The antimicrobial combinations of GL with four antibiotics resulted in additive effect in most instances, synergism in two instances, and antagonism in two instances.
|
GL
|
antibiotics
|
EFFECT
|
10319155.xml
|
DDI-MedLine.d84.s4
|
DDI-MedLine.d84.s4.p0
|
Indinavir may be taken with a light meal 1 h following the administration of 400 mg of didanosine.
|
Indinavir
|
didanosine
|
ADVISE
|
11120981.xml
|
DDI-MedLine.d79.s5
|
DDI-MedLine.d79.s5.p0
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
phenytoin
|
tolbutamide
|
MECHANISM
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p19
|
Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
|
ergot alkaloids
|
SPRYCEL
|
ADVISE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s15
|
DDI-DrugBank.d48.s15.p87
|
Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).
|
cimetidine
|
phenytoin
|
NONE
|
Caffeine_ddi.xml
|
DDI-DrugBank.d89.s3
|
DDI-DrugBank.d89.s3.p17
|
Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.
|
sulfinpyrazone
|
nitrofurantoin
|
MECHANISM
|
Nitrofurantoin_ddi.xml
|
DDI-DrugBank.d276.s2
|
DDI-DrugBank.d276.s2.p5
|
include terfenadine, astemizole, cisapride, midazolam, and triazolam.
|
midazolam
|
triazolam
|
NONE
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s16
|
DDI-DrugBank.d78.s16.p9
|
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .
|
apomorphine
|
dolasetron
|
ADVISE
|
Apomorphine_ddi.xml
|
DDI-DrugBank.d357.s0
|
DDI-DrugBank.d357.s0.p27
|
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.
|
PROLEUKIN
|
tamoxifen
|
EFFECT
|
Aldesleukin_ddi.xml
|
DDI-DrugBank.d114.s5
|
DDI-DrugBank.d114.s5.p3
|
The effects of medicinal products with similar properties such as inotropes milrinone, enoximone, amrinone, olprinone and cilostazol may be exacerbated by anagrelide.
|
cilostazol
|
anagrelide
|
EFFECT
|
Anagrelide_ddi.xml
|
DDI-DrugBank.d75.s14
|
DDI-DrugBank.d75.s14.p14
|
Drug Interaction with Erythromycin and Ketoconazole Fexofenadine has been shown to exhibit minimal (ca. 5%) metabolism.
|
Erythromycin
|
Ketoconazole
|
NONE
|
Fexofenadine_ddi.xml
|
DDI-DrugBank.d466.s0
|
DDI-DrugBank.d466.s0.p0
|
Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.
|
Valdecoxib
|
S-warfarin
|
MECHANISM
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s24
|
DDI-DrugBank.d328.s24.p1
|
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.
|
phenobarbital
|
phenytoin
|
NONE
|
Cortisone acetate_ddi.xml
|
DDI-DrugBank.d487.s1
|
DDI-DrugBank.d487.s1.p0
|
Careful observations on hepatotoxicity are suggested when acetaminophen is prescribed with caffeine.
|
acetaminophen
|
caffeine
|
EFFECT
|
3969689.xml
|
DDI-MedLine.d55.s4
|
DDI-MedLine.d55.s4.p0
|
Chlorotrianisene may interact with antidepressants, aspirin, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, cyclosporine, dantrolene, nicotine, somatropin, tamoxifen, and warfarin.
|
Chlorotrianisene
|
bromocriptine
|
INT
|
Chlorotrianisene_ddi.xml
|
DDI-DrugBank.d446.s0
|
DDI-DrugBank.d446.s0.p3
|
Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.
|
TIKOSYN
|
verapamil
|
MECHANISM
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s7
|
DDI-DrugBank.d558.s7.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
miconazole
|
sulfonamides
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p1201
|
Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
|
Vitamin D2
|
Vitamin D3
|
NONE
|
Cholecalciferol_ddi.xml
|
DDI-DrugBank.d404.s0
|
DDI-DrugBank.d404.s0.p7
|
Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely.
|
indinavir
|
indinavir
|
NONE
|
11120981.xml
|
DDI-MedLine.d79.s1
|
DDI-MedLine.d79.s1.p1
|
Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.
|
Probenecid
|
zalcitabine
|
NONE
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s20
|
DDI-DrugBank.d263.s20.p3
|
If desipramine hydrochloride is to be combined with other psychotropic agents such as tranquilizers or sedative/hypnotics, careful consideration should be given to the pharmacology of the agents employed since the sedative effects of desipramine and benzodiazepines (e.g., chlordiazepoxide or diazepam) are additive.
|
desipramine hydrochloride
|
tranquilizers
|
EFFECT
|
Desipramine_ddi.xml
|
DDI-DrugBank.d386.s23
|
DDI-DrugBank.d386.s23.p1
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
quinidine
|
carbamazepine
|
NONE
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p75
|
Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine.
|
MPTP
|
methamphetamine
|
NONE
|
3871245.xml
|
DDI-MedLine.d73.s0
|
DDI-MedLine.d73.s0.p2
|
Before taking glimepiride, tell your doctor if you are taking any of the following medicines: - aspirin or another salicylate such as magnesium/choline salicylate (Trilisate), salsalate (Disalcid, others), choline salicylate (Arthropan), magnesium salicylate (Magan), or bismuth subsalicylate (Pepto-Bismol);
|
glimepiride
|
salsalate
|
ADVISE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s1
|
DDI-DrugBank.d521.s1.p4
|
When amiloride HCl is administered concomitantly with an angiotensin-converting enzyme inhibitor, the risk of hyperkalemia may be increased.
|
amiloride
|
angiotensin-converting enzyme inhibitor
|
EFFECT
|
Amiloride_ddi.xml
|
DDI-DrugBank.d356.s0
|
DDI-DrugBank.d356.s0.p0
|
Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.
|
fexofenadine hydrochloride
|
magnesium
|
MECHANISM
|
Fexofenadine_ddi.xml
|
DDI-DrugBank.d466.s19
|
DDI-DrugBank.d466.s19.p7
|
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.
|
acetylsalicylic acid
|
fondaparinux sodium
|
NONE
|
Fondaparinux sodium_ddi.xml
|
DDI-DrugBank.d15.s0
|
DDI-DrugBank.d15.s0.p29
|
Experience with co-administration of HMG-CoA reductase inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving Fentanyl.
|
HMG-CoA reductase inhibitors
|
Fentanyl
|
ADVISE
|
Daptomycin_ddi.xml
|
DDI-DrugBank.d337.s3
|
DDI-DrugBank.d337.s3.p5
|
Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.
|
Selective serotonin reuptake inhibitors
|
5-HT1 agonists
|
EFFECT
|
Frovatriptan_ddi.xml
|
DDI-DrugBank.d426.s3
|
DDI-DrugBank.d426.s3.p5
|
Beta-blockers, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.
|
lithium
|
insulin
|
EFFECT
|
Insulin Glargine recombinant_ddi.xml
|
DDI-DrugBank.d527.s3
|
DDI-DrugBank.d527.s3.p8
|
In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore, insulin requirements.
|
androgens
|
insulin
|
EFFECT
|
Dromostanolone_ddi.xml
|
DDI-DrugBank.d129.s3
|
DDI-DrugBank.d129.s3.p0
|
Co-administration of TIKOSYN with verapamil resulted in increases in dofetilide peak plasma levels of 42%, although overall exposure to dofetilide was not significantly increased.
|
dofetilide
|
dofetilide
|
NONE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s7
|
DDI-DrugBank.d558.s7.p5
|
Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).
|
enalapril
|
diuretics
|
EFFECT
|
Enalapril_ddi.xml
|
DDI-DrugBank.d107.s3
|
DDI-DrugBank.d107.s3.p2
|
There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.
|
erythromycin
|
tacrolimus
|
INT
|
Erythromycin_ddi.xml
|
DDI-DrugBank.d397.s8
|
DDI-DrugBank.d397.s8.p2
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
NIMBEX
|
lincomycin
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p20
|
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.
|
acetaminophen
|
theophylline
|
NONE
|
11206047.xml
|
DDI-MedLine.d111.s5
|
DDI-MedLine.d111.s5.p59
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
topiramate
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p37
|
In these patients whose hypertension was controlled with nifedipine, Vardenafil 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.
|
nifedipine
|
Vardenafil
|
EFFECT
|
Vardenafil_ddi.xml
|
DDI-DrugBank.d198.s27
|
DDI-DrugBank.d198.s27.p0
|
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
|
quinolone
|
magnesium
|
MECHANISM
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s8
|
DDI-DrugBank.d123.s8.p1
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
EQUETROTM
|
risperidone
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p35
|
Protease inhibitors: Amprenavir, lopinavir, nelfinavir, and ritonavir have been shown to decrease plasma levels of combination hormonal contraceptives;
|
lopinavir
|
combination hormonal contraceptives
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s32
|
DDI-DrugBank.d485.s32.p11
|
Iodine or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.
|
iodine
|
iodine
|
NONE
|
Carbimazole_ddi.xml
|
DDI-DrugBank.d213.s0
|
DDI-DrugBank.d213.s0.p5
|
In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
|
serotoninergic agents
|
venlafaxine
|
NONE
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s0
|
DDI-DrugBank.d423.s0.p25
|
Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine.
|
Phenothiazines
|
epinephrine
|
EFFECT
|
Lidocaine_ddi.xml
|
DDI-DrugBank.d564.s1
|
DDI-DrugBank.d564.s1.p1
|
Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.
|
phenobarbital
|
AEDs
|
NONE
|
Tiagabine_ddi.xml
|
DDI-DrugBank.d277.s12
|
DDI-DrugBank.d277.s12.p13
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
EQUETROTM
|
fluvoxamine
|
MECHANISM
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p10
|
Aminosalicylic acid may also decrease the absorption of vitamin B12, which can lead to a deficiency.
|
Aminosalicylic acid
|
vitamin B12
|
MECHANISM
|
Aminosalicylic Acid_ddi.xml
|
DDI-DrugBank.d22.s2
|
DDI-DrugBank.d22.s2.p0
|
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.
|
ritonavir
|
budesonide
|
ADVISE
|
Budesonide_ddi.xml
|
DDI-DrugBank.d144.s1
|
DDI-DrugBank.d144.s1.p14
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
anticoagulant
|
sulfinpyrazone
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p45
|
As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.
|
COREG
|
diltiazem
|
ADVISE
|
Carvedilol_ddi.xml
|
DDI-DrugBank.d269.s17
|
DDI-DrugBank.d269.s17.p6
|
Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as propranolol and metoprolol.
|
dopamine
|
metoprolol
|
EFFECT
|
Dopamine_ddi.xml
|
DDI-DrugBank.d325.s4
|
DDI-DrugBank.d325.s4.p2
|
Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.
|
magnesium
|
lomefloxacin
|
MECHANISM
|
Lomefloxacin_ddi.xml
|
DDI-DrugBank.d516.s3
|
DDI-DrugBank.d516.s3.p29
|
If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.
|
ranitidine
|
aluminum hydroxide
|
NONE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s5
|
DDI-DrugBank.d558.s5.p22
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
fenoprofen
|
tolbutamide
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p919
|
Although the clinical significance is not known, it is not recommended that cefditoren pivoxil be taken concomitantly with antacids.
|
cefditoren pivoxil
|
antacids
|
ADVISE
|
Cefditoren_ddi.xml
|
DDI-DrugBank.d550.s1
|
DDI-DrugBank.d550.s1.p0
|
Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.
|
NSAID
|
digoxin
|
EFFECT
|
Diclofenac_ddi.xml
|
DDI-DrugBank.d249.s5
|
DDI-DrugBank.d249.s5.p9
|
If a patient requires TIKOSYN and anti-ulcer therapy, it is suggested that omeprazole, ranitidine, or antacids (aluminum and magnesium hydroxides) be used as alternatives to cimetidine, as these agents have no effect on the pharmacokinetic profile of TIKOSYN.
|
omeprazole
|
ranitidine
|
NONE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s5
|
DDI-DrugBank.d558.s5.p15
|
Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
|
azole antifungal agents
|
cannabinoids
|
NONE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s25
|
DDI-DrugBank.d558.s25.p15
|
MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.
|
MAO inhibitors
|
antihistamines
|
EFFECT
|
Diphenhydramine_ddi.xml
|
DDI-DrugBank.d296.s1
|
DDI-DrugBank.d296.s1.p0
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
adrenocortical steroids
|
cholestyramine
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p30
|
- a nonsteroidal anti-inflammatory drug (NSAID) such as ibuprofen (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, Orudis KT, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);
|
indomethacin
|
naproxen
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s2
|
DDI-DrugBank.d521.s2.p260
|
The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromonab-CD3.
|
azathioprine
|
muromonab-CD3
|
NONE
|
Basiliximab_ddi.xml
|
DDI-DrugBank.d544.s5
|
DDI-DrugBank.d544.s5.p8
|
Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
|
barbiturates
|
nonsteroidal anti-inflammatory
|
NONE
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s0
|
DDI-DrugBank.d260.s0.p81
|
Products containing calcium and other multivalent cations (such as aluminum, magnesium, iron) are likely to interfere with absorption of Ibandronate.
|
calcium
|
Ibandronate
|
MECHANISM
|
Ibandronate_ddi.xml
|
DDI-DrugBank.d440.s1
|
DDI-DrugBank.d440.s1.p3
|
Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.
|
p-aminosalicylic acid
|
lithium
|
NONE
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s4
|
DDI-DrugBank.d411.s4.p52
|
- Drugs that may decrease plasma phenytoin concentrations include: carbamazepine, chronic alcohol abuse, reserpine
|
phenytoin
|
carbamazepine
|
MECHANISM
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s12
|
DDI-DrugBank.d40.s12.p0
|
Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin, the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin.
|
phenytoin
|
BUSULFEX
|
NONE
|
Busulfan_ddi.xml
|
DDI-DrugBank.d72.s3
|
DDI-DrugBank.d72.s3.p3
|
Drug Interactions: The central anticholinergic syndrome can occur when anticholinergic agents such as AKINETON are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain narcotic analgesics such as meperidine, the phenothiazines and other antipsychotics, tricyclic antidepressants, certain antiarrhythmics such as the quinidine salts, and antihistamines.
|
AKINETON
|
tricyclic antidepressants
|
EFFECT
|
Biperiden_ddi.xml
|
DDI-DrugBank.d401.s0
|
DDI-DrugBank.d401.s0.p13
|
NSAIDs may decrease the hemodynamic effects of hydralazine;
|
NSAIDs
|
hydralazine
|
EFFECT
|
Hydralazine_ddi.xml
|
DDI-DrugBank.d31.s7
|
DDI-DrugBank.d31.s7.p0
|
Some quinolones, including ciprofloxacin, have also been shown to interfere with the metabolism of caffeine.
|
ciprofloxacin
|
caffeine
|
MECHANISM
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s0
|
DDI-DrugBank.d123.s0.p2
|
Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic agents, eg, tolbutamide and chlorpropamide, by inhibiting their metabolism in the liver.
|
anticoagulants
|
tolbutamide
|
MECHANISM
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s88
|
DDI-DrugBank.d64.s88.p1
|
Drug-Drug Interactions Given the primary CNS effects of aripiprazole, caution should be used when ABILIFY is taken in combination with other centrally acting drugs and alcohol.
|
ABILIFY
|
alcohol
|
ADVISE
|
Aripiprazole_ddi.xml
|
DDI-DrugBank.d509.s0
|
DDI-DrugBank.d509.s0.p4
|
Clinical trials have indicated that Pulmozyme can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral antibiotics, bronchodilators, enzyme supplements, vitamins, oral or inhaled corticosteroids, and analgesics.
|
antibiotics
|
vitamins
|
NONE
|
Dornase Alfa_ddi.xml
|
DDI-DrugBank.d93.s0
|
DDI-DrugBank.d93.s0.p6
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.